PharmaResearch Products

What PharmaResearch Products does

PharmaResearch Products Co., Ltd. is a South Korea-based, KOSDAQ-listed (214450) regenerative medicine company founded in 1993 that develops, manufactures, and commercializes PDRN (Polydeoxyribonucleotide)-based products for aesthetic, dermatological, and emerging oncology applications. The company's core technology is its proprietary DOT (DNA Optimizing Technology) platform, which extracts DNA from salmon germ cells and optimizes it as a regenerative active substance, deployed through multiple delivery systems including PLGA nanoparticles, lipid nanoparticles, microneedles, exosome encapsulation, and chitosan carriers. PharmaResearch holds an 88.0% share of the PDRN material source market and 70.3% share of single-ingredient injectables as of 2025, and its branded REJURAN franchise is recognized as Korea's No.1 medical aesthetic brand.

The company operates a dual-track business model spanning professional aesthetics and consumer skincare. In the professional channel, REJURAN PN-based skin boosters are sold to aesthetic practitioners, with expansion underway across Western Europe (via Laboratoires VIVACY), Brazil (via DermaDream), and existing presence in Chile and Peru. In the consumer channel, REJURAN Cosmetics products, powered by the patented c-PDRN ingredient, launched at Sephora U.S. (approximately 380 stores and sephora.com) in March 2026, supplemented by Amazon and TikTok Shop distribution. A third leg, the FDA IND-cleared nano anticancer drug candidate PRD-101, entered Phase 1 trials in February 2026 for locally advanced or metastatic solid tumors, representing entry into oncology using the DOT drug delivery platform.

Revenue mechanics are diversified across multiple channels and geographies, though the company is in a capital-intensive expansion phase. It raised KRW 200 billion (~$144M) from CVC Capital Partners in 2026, acquired TuringBio (AI digital therapeutics) in 2024 and announced the acquisition of CG USA (FDA-registered Los Angeles cosmetics manufacturer) in June 2026 to localize U.S. manufacturing. The company maintains operations in South Korea (Gangneung, Seoul) and the United States (Los Angeles), with 101-250 employees, and is led by CEOs Jung Sangsoo and Ahn Wonjun. The export business has grown approximately 5x over recent years, with U.S. exports surging over 400% YoY for three consecutive quarters in 2023.

Name

PharmaResearch Products

Legal name

PharmaResearch Co., Ltd.

Website

https://pharmaresearch.co.kr

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

101–250 employees

Short description

PharmaResearch Products is a South Korea-based KOSDAQ-listed regenerative medicine company that develops PDRN-based aesthetic injectables, consumer skincare (REJURAN Cosmetics), and an FDA-cleared nano anticancer drug candidate (PRD-101) using its proprietary DOT DNA optimization technology, selling to aesthetic practitioners and global retail partners including Sephora.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Pharmaceuticals and Derma-Cosmetics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (4242), Health and Personal Care Retailers (456)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Regenerative medicine
• PDRN skin boosters
• Aesthetic injectables
• Derma-cosmetic skincare
• DNA biotechnology

Headquarters

HQ city

Gangneung

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel

Revenue model

1. PDRN Injectables: Sales of PDRN-based injectable skin boosters for aesthetic medicine, with salmon DNA-derived PDRN as primary material source at 88.0% market share in 2025. Single-ingredient injectables dominate with 70.3% market share.
2. REJURAN Cosmetics (Consumer Skincare): Consumer derma-cosmetic skincare products sold through Sephora retail and e-commerce channels including Amazon and TikTok Shop. Revenue from Korea-manufactured products with plans for local U.S. manufacturing via CG USA acquisition.
3. Nano Anticancer Drug (PRD-101): Phase 1 clinical trial stage nano anticancer drug candidate leveraging proprietary DOT drug delivery platform. Revenue potential pending regulatory approval.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

PharmaResearch Products is a biopharmaceutical company that develops, manufactures, and sells PDRN-based regenerative medicine products using its proprietary DNA Optimizing Technology (DOT) platform. Its commercial portfolio includes the REJURAN line of PN-based skin booster injectables for medical aesthetic practitioners and the REJURAN Cosmetics derma-cosmetic consumer skincare line featuring c-PDRN-based ampoules, creams, and masks sold through retail and e-commerce channels. The company is also developing PRD-101, a next-generation nano anticancer drug candidate leveraging the DOT drug delivery platform that received FDA IND clearance for Phase 1 clinical trials.

Product overview

PharmaResearch Products is a South Korea-based regenerative medicine company offering a dual product portfolio comprising pharmaceutical and derma-cosmetic offerings. The core pharmaceutical line includes REJURAN, a PN-based skin booster leveraging the proprietary DOT™ DNA Optimizing Technology, and PRD-101, a nano anticancer drug candidate in clinical development. The consumer-facing derma-cosmetic line is branded as REJURAN Cosmetics, featuring c-PDRN-based skincare products including ampoules and creams, distributed through Sephora, Amazon, and other retail channels. The company operates manufacturing facilities in South Korea and is expanding into the U.S. market through the planned acquisition of CG USA.

Differentiator

Problem solved

Functional benefit

Brands

• REJURAN Cosmetics: Korea's No.1 medical aesthetic brand developed by PharmaResearch, powered by patented c-PDRN ingredient derived from sustainably sourced salmon DNA. Products include Turnover Ampoule, Dual Effect Ampoule, and other science-led skincare products available at Sephora and Amazon.
• REJURAN

Products and services

• REJURAN PN-based skin booster product for aesthetic and regenerative medicine applications utilizing PharmaResearch's proprietary DOT™ DNA Optimizing Technology. Marketed to healthcare professionals for clinical applications in anti-aging, skin rejuvenation, and regenerative treatments for aesthetic medicine practitioners.
• REJURAN Cosmetics Consumer derma-cosmetic skincare line powered by patented c-PDRN ingredient derived from sustainably sourced salmon DNA. Includes hero products such as REJURAN Turnover Ampoule, Dual Effect Ampoule, Dual Effect Ampoule In Mask, and Pore Tightening Cream, distributed through Sephora, Amazon, and TikTok Shop for retail consumers seeking science-led skincare.
• PRD-101 Next-generation nano anticancer drug candidate developed using PharmaResearch's proprietary nucleotide-based DOT™ drug delivery platform. Currently in Phase 1 clinical trials targeting patients with locally advanced or metastatic solid tumors across up to seven U.S. clinical sites.
• REJURAN Pore Tightening Cream New consumer skincare product addition to the REJURAN Cosmetics line focused on pore tightening, leveraging patented c-PDRN ingredient derived from salmon DNA for at-home skincare applications.

Quantifiable outcome

• Over 400% year-over-year US export growth for three consecutive quarters in 2023
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• CG USA (Cosmetic Group USA)coreStrategic or Co-development Partner · 30 June 2026PharmaResearch signed agreement to acquire CG USA, a California-based cosmetics OEM and ODM manufacturer with FDA-registered facility in Los Angeles. The acquisition establishes local manufacturing base for REJURAN Cosmetics in North America, enabling improved supply chain efficiency, logistics, and distribution. CG USA provides capabilities spanning product planning, formula development, manufacturing, filling, packaging and quality control. Founded in 1986, CG USA holds ISO 22716 certification and provides OEM/ODM services to cosmetics brands.
• Cosmo Group Inc.minorImplementation/ SI/ Consulting Partner · 30 June 2026Transaction advisor for the CG USA acquisition. Financial terms were not disclosed.
• Laboratoires VIVACYcoreStrategic or Co-development Partner · 1 April 2026Partnership to co-develop covalently crosslinked HA-PDRN combination injectables projected to potentially become the clinical reference standard for PDRN skin boosters in the EU market. Laboratoires VIVACY serves as European distribution partner, supporting PharmaResearch's five-market Western Europe expansion across Benelux, UK, Switzerland, Italy, Poland, France, and Germany.
• ConnectsminorStrategic or Co-development Partner · 16 March 2026PharmaResearch joined as strategic investor in Connects' KRW 15 billion Series C funding round. Partnership combines Connects' recombinant protein technology with PharmaResearch's global commercialization capabilities. Funds support CNT201 development for Dupuytren's contracture treatment with plans to expand indications to include cellulitis.
• DermaDreamcoreChannel Partner/ Reseller/ Distributor · 1 January 2026Exclusive supply agreement for Rejuran product signed at IMCAS World 2026 in Paris. DermaDream serves as exclusive distribution partner in Brazil, leveraging established sales network and regulatory expertise. PharmaResearch views Brazil as a key strategic market in Latin America, building on existing experience in Chile and Peru.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Laboratoires VIVACY: VIVACY is a French developer of hyaluronic acid-based injectables (Stylage) that partners with PharmaResearch on covalently crosslinked HA-PDRN combination injectables. Directly comparable as a specialized regenerative/aesthetic injectable partner with overlapping customer channel in EU.
• Hugel, Inc. Hugel is a South Korean biopharmaceutical company with a leading aesthetic injectable business (Botulax, Dermalax HA fillers) and global distribution. Directly comparable to PharmaResearch as a Korean-listed aesthetic medicine company using proprietary bio-ingredients across clinical injectables and derma-cosmetics.
• Medytox: Medytox is a Korean-listed biopharma specializing in botulinum toxin and hyaluronic acid fillers for medical aesthetics. Comparable to PharmaResearch in product category (injectable regenerative/aesthetic), customer base (clinicians and aesthetic practitioners), and Korean public-company profile with global commercial build-out.
• Teoxane Laboratories: Teoxane is a Swiss HA filler specialist (Teosyal RHA range) with global aesthetic distribution. Comparable to PharmaResearch in specializing in regenerative HA-based injectables targeting aesthetic practitioners and competing in the EU markets where REJURAN is expanding.

Broad incumbents

• Galderma: Galderma is a global dermatology-focused company with a deep aesthetic injectables portfolio (Restylane, Sculptra, Dysport) plus derma-cosmetics. Comparable to PharmaResearch in combining professional injectables with consumer skincare and targeting the same aesthetic dermatology customer.
• AbbVie (Allergan Aesthetics): AbbVie's Allergan Aesthetics unit (Botox, Juvéderm, CoolSculpting, SkinMedica) is the global aesthetic market leader. Comparable to PharmaResearch as the dominant incumbent defining clinical and retail standards PharmaResearch must compete against, especially with REJURAN at Sephora.
• Dermalogica (Unilever): Dermalogica is a professional skincare brand distributed through skincare professionals and select retail. Comparable to REJURAN Cosmetics as a science-led, professional-channel skincare brand pursuing the same hybrid professional/retail consumer pattern.
• SkinCeuticals (L'Oréal): SkinCeuticals is L'Oréal's medical-grade skincare brand sold through Sephora, physicians, and med-spas. Comparable to REJURAN Cosmetics as a clinical-claim derma-cosmetic SKU already anchored in Sephora's medical-grade skincare assortment that REJURAN is joining.
• Merz Aesthetics: Merz Aesthetics markets injectables (Belotero, Radiesse) and medical skincare lines globally. Comparable to PharmaResearch as a diversified aesthetics incumbent competing in HA fillers and regenerative/collagen-stimulating injectables in the same physician channels.
• LG Chem Life Sciences: LG Chem has a sizable life sciences division producing aesthetic fillers (e.g., YVOIRE), biologics, and specialty pharma. Comparable to PharmaResearch as a broader Korean player operating in regenerative/aesthetic pharmaceuticals with greater scale and capital resources.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmaresearch-corporation

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaResearch Products